New book by Larry Connors Click here Improve your trading - See how
Optimer Pharmaceuticals Inc. (NASDAQ: OPTR | Quote | Chart | News | PowerRating) a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products. The company develops products that treat gastrointestinal infections and related diseases. Its two late-stage anti-infective product candidates include OPT-80, an antibiotic in two Phase III registration trials for the treatment of Clostridium difficile-infections/Clostridium difficile-associated disease, the common nosocomial diarrhea; and Prulifloxacin, an antibiotic in two Phase III trials for the treatment of infectious diarrhea in travelers, a community-acquired infection, which is caused by a range of bacteria. It also develops OPT-1068/CEM-101, a pre-clinical antibiotic against respiratory tract infections; an OPopS drug discovery platform; OPT-822, a carbohydrate-based immunostimulant therapy for the treatment of metastatic breast cancer that completed phase I trials; and OPT-88 as a disease-modifying intra-articular and as a therapy for osteoarthritis. The company has a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds. Optimer Pharmaceuticals was founded 1998 and is headquartered in San Diego, California. With 29.7 million shares outstanding and 1.36 million shares declared short as of September 2008, there is no longer a failure to deliver in shares of OPTR. According to quarterly data provided by the SEC, there were still 286,745 shares of OPTR that were failing-to-deliver as of February 14, 2007.
Osiris Therapeutics Inc. (NASDAQ: OSIR | Quote | Chart | News | PowerRating) a biotechnology company, commercializes stem cell products from adult bone marrow in the United States. It develops and markets products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The company's products include Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, and Crohn's disease; in phase II clinical trials for the treatment of Type I diabetes and acute myocardial infarction; in preclinical stage for the treatment of acute radiation syndrome; and Chondrogen, a phase I/II clinical trial used for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with JCR Pharmaceuticals Co., Ltd.; Genzyme Corporation; Juvenile Diabetes Research Foundation; and Blackstone Medical, Inc. The company was founded in 1992 and is headquartered in Columbia, Maryland. With 31.81 million shares outstanding and 2.8 million shares declared short as of September 2008, there is no longer a failure to deliver in shares of OSIR. According to quarterly data provided by the SEC, there were still 727,449 shares of OSIR that were failing-to-deliver as of June 29, 2007.
Open Text Corp. (NASDAQ: OTEX | Quote | Chart | News | PowerRating) develops, markets, sells, licenses, and supports Enterprise Content Management (ECM) solutions primarily in North America and Europe. The company?s ECM solutions help customers manage their critical business content, including version revisions and compliance with regulatory requirements. Its principal product, Livelink, enables corporations to manage traditional forms of content, such as images, office documents, graphics, and drawings, as well as to manage electronic content, including Web pages, email, and video. The company also offers ECM solutions that bring together people, processes, and information, as well as software, which combines collaboration with content management, transforming information into knowledge that provides the foundation for innovation, compliance, and accelerated growth. In addition, Open Text Corporation provides training, consulting, hosting services, and customer support programs. It has strategic alliances with SAP AG, Microsoft Corporation, and Oracle Corporation. The company was founded in 1991 and is headquartered in Waterloo, Canada. With 51.16 million shares outstanding and 17.92 million shares declared short as of September 2008, there is no longer a failure to deliver in shares of OTEX. According to quarterly data provided by the SEC, there were still 920,948 shares of OTEX that were failing-to-deliver as of December 29, 2006.
Pacific Capital Bancorp (NASDAQ: PCBC | Quote | Chart | News | PowerRating) operates as the holding company for Pacific Capital Bank, N.A., which provides a range of commercial and consumer banking services to households, professionals, and businesses primarily in the central coast of California. The company primarily offers its banking services under Santa Barbara Bank & Trust, First National Bank of Central California, South Valley National Bank, San Benito Bank, and First Bank of San Luis Obispo brand names. It offers a range of deposit products, including NOW accounts, money market deposit accounts, savings accounts, time certificates of deposit, interest bearing deposits, and demand deposits. The company also provides various loans comprising real estate loans, home equity lines and loans, consumer loans, leases, and demand deposit overdraft protection products, as well as commercial, industrial, and agricultural loans. In addition, it offers safe deposit boxes, travelers' checks, money orders, foreign exchange services, and cashiers checks. Further, the company provides trust and investment advisory services, as well as a range of wealth management services. As of December 31, 2007, it operated 50 retail branches and 14 loan production offices. Pacific Capital Bancorp was founded in 1960 and is based in Santa Barbara, California. With 46.19 million shares outstanding and 10.17 million shares declared short as of September 2008, there is no longer a failure to deliver in shares of PCBC. According to quarterly data provided by the SEC, there were still 314,587 shares of PCBC that were failing-to-deliver as of April 29, 2008.
P.F.Chang's China Bistro Inc. (NASDAQ: PFCB | Quote | Chart | News | PowerRating) through its subsidiaries, engages in the ownership and operation of restaurants in the United States. The company operates restaurants under the aEUR~P.F. Chang's China Bistro' and aEUR~Pei Wei Asian Diner' names. As of December 31, 2007, it operated 172 full service Bistro restaurants, 144 quick casual Pei Wei restaurants, and 1 Taneko Japanese Tavern restaurant. The company was founded in 1996 and is based in Scottsdale, Arizona. With 23.78 million shares outstanding and 8.89 million shares declared short as of September 2008, there is no longer a failure to deliver in shares of PFCB. According to quarterly data provided by the SEC, there were still 710,886 shares of PFCB that were failing-to-deliver as of March 28, 2008.
Pozen Inc. (NASDAQ: POZN | Quote | Chart | News | PowerRating) focuses on the development of pharmaceutical products for the treatment of acute and chronic pain, and other pain-related conditions. It has development and commercialization alliances with GlaxoSmithKline for Treximet, which is used for the acute treatment of migraine attacks with or without aura in adults; and AstraZeneca for proprietary fixed dose combinations of naproxen with the proton pump inhibitor esomeprazole magnesium in a single tablet for conditions, such as osteoarthritis and rheumatoid arthritis in patients who are at risk for developing non-steroidal anti-inflammatory drug-associated gastric ulcers. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina. With 29.76 million shares outstanding and 6.44 million shares declared short as of September 2008, there is no longer a failure to deliver in shares of POZN. According to quarterly data provided by the SEC, there were still 1,960,222 shares of POZN that were failing-to-deliver as of April 21, 2008.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,200,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
15260 Ventura Blvd., Ste. 2200
Sherman Oaks, CA 91403
© Copyright 2009 The Connors Group, Inc.
